Description
Moving from "hit-to-lead" to the preclinical stage requires deep characterization, which is addressed by our Drug Development Services. This portfolio focuses on predicting the physiological and metabolic trajectories of optimized candidates. We leverage specialized predictive modeling for ADMET properties (Absorption, Distribution, Metabolism, Excretion, and Toxicity), physiological-based pharmacokinetic (PBPK) simulations, and formulation stability modeling. This ensures candidates exhibit optimal drug-like profiles suitable for downstream manufacturing and clinical evaluation.